Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

CIPHER PHARMS INC ORD by Cipher Pharmaceuticals, Inc.

Cipher Pharmaceuticals

RBC Capital analyst Daniel Perlin maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Outperform and raises the price target from $301 to $322.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Accenture, Raises Price Target to $322

Baird analyst Tristan Gerra upgrades Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) from Neutral to Outperform and raises the price target from $22 to $30.

Upgrades

LAZR

Baird Upgrades Luminar Technologies to Outperform, Raises Price Target to $30

RBC Capital analyst Keith Mackey maintains Ensign Energy Services (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ESI#TSX">ESI</a>) with a Sector Perform and raises the price target from C$2.25 to C$3.

TSX:ESI

RBC Capital Maintains Sector Perform on Ensign Energy Services, Raises Price Target to C$3

Chinese electric vehicle manufacturer Nio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) has a strong following among retail investors, who are convinced of the company&#39;s potential to thrive in the electric vehicle market.&nbsp;
Nio&#39;s Debut, Initial Years: Nio&#39;s ADSs were listed on the NYSE in mid-September 2018 following an initial public offering of 160 million shares priced at $6.26 each. The stock closed the debut session with a modest gain of 5.4% at $6.60 and went on to more than double over the next following sessions.
Subsequently, the stock was largely rangebound between $6 and $8 until the middle of March 2019.
Nio, founded as a pure play EV startup in China in 2014, launched its first mass-manufactured model, the ES8, an all-electric SUV, in December 2017, and deliveries of the vehicle began in June 2018.
Then came the ES6, also an SUV, which was commercially made available in June 2019. The third vehicle model from Nio&#39;s stable was the EC6. Nio <a href="https://www.benzinga.com/news/20/09/17661392/nio-begins-delivery-of-electric-ec6-suv-what-you-need-to-know">began</a> delivering this vehicle to its customers in September 2020.
Cash Crunch Comes To Haunt Nio:&nbsp; As Nio&#39;s cost of operations ballooned, the top-line growth and the existing avenues of financing were inadequate to finance its daily operations.
In the earnings report for the fourth quarter of 2019, Nio sounded a &quot;going concern&quot; warning, stating there was substantial doubt about its ability to continue as a going concern&nbsp;given the mounting losses, net cash outflows, negative working capital, negative equity and uncertainties on consummation of the financing projects.
As of Dec. 31, 2019, the company had cash and cash equivalents of $151.7 million, a measly sum relative to the huge funding needs of a company operating in a capital-intensive sector.
In 2019, the company delivered 20,565 vehicles and reported revenues of $1.124 billion.
It was amid this fundamental turmoil that&nbsp;Nio&#39;s stock fell precipitously to a low of $1.19 in October&nbsp;2019, a more than 80% drop from its IPO price. After staging a modest recovery, the stock closed the year at $4.02.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21494218/tesla-nio-shares-diverge-what-does-it-signal-for-the-ev-companies">Tesla, Nio Shares Diverge: What Does It Signal For The EV Companies?</a>
Nio&#39;s Turnaround Begins: In mid-January 2020, Nio confirmed it has explored financing and strategic opportunities with Guangzhou Automobile Group. Subsequently, in the month of February, through two private placements, the company raised a combined $200 million.
Nio announced on Feb. 25 it has entered into a collaboration framework agreement with the municipal government of Hefei, in Anhui province, where the company&#39;s main manufacturing hub is located.
The agreement provided for the local government supporting Nio with resources and funding. In return, Nio opted to relocate its China headquarters from Shanghai to Hefei.
Thereafter, the company steadily shored up its cash position through a combination of debt and equity offerings and strategic investments.
By the end of 2020, the company more than doubled its revenues to $2.492 billion and delivered 43,728 vehicles. More importantly, its cash position swelled to $6.5 billion at the end of 2020.
Even amid the pandemic, the company managed its fundamental performance well. Deliveries did take a hit in January and February before recovering in March&nbsp;as the company pushed ahead with its products and services focus.
The stock dipped to a low of $2.11 in mid-March 2020 but came roaring back up in the second half.
From $4.02 at the end of 2019, it closed 2020 at $48.74, an 1,100% annual gain.
The stock advanced further in 2021, hitting an all-time high of $66.99 on Jan. 11. Since then, it has pulled back and consolidated amid industry-wide concerns, macroeconomic worries and valuation fears.
Nio&#39;s Superior Returns: If an investor had put in $1,000 in Nio stock&nbsp;at the end of 2019, they&nbsp;would have bought roughly 249 shares.
Taking the stock&#39;s closing price of $46.91 on June 21, 2021, the value of the investor&#39;s Nio holdings would now be $11,681, an&nbsp;1,168% gain over a timeframe of 18 months.
What&#39;s In Store For Nio: Nio has evolved as a provider of EVs catering to the premium segment, and its premium reputation continues to grow. Services such as battery-as-a-service and autonomous driving-as-a-service are aimed at making Nio vehicles affordable.&nbsp;
Nio&#39;s yet-to-be launched ET7 sedan recently <a href="https://www.benzinga.com/news/21/06/21644979/nios-et7-sedan-snags-red-dot-product-design-award">won</a> the 2021 Red Dot Product Design Award&nbsp;from Red Dot GmbH, a German organization.
The company has also set the ball rolling on its international expansion with its Norwegian market entry.&nbsp;
At the end of the first quarter of 2021, Nio&#39;s long-term debt stood at $2.1 billion and its cash position was at $7.3 billion.
The company has also managed to keep its costs in check and this is reflected in the inflection in its gross margin to positive territory.
The stock trajectory going forward will largely hinge on how well Nio is able to continue with its fundamental improvement.
Photo: a Nio battery. Courtesy photo.&nbsp;

Global

Trading Ideas

How Much A $1,000 Nio Investment In 2019, When The EV Stock Was Emerging From Liquidity Crunch, Would Be Worth Today

RBC Capital analyst Darko Mihelic initiates coverage on Sagicor Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SFC#TSX">SFC</a>) with a Outperform rating and announces Price Target of C$8.

Initiation

TSX:SFC

RBC Capital Initiates Coverage On Sagicor Financial with Outperform Rating, Announces Price Target of C$8

UBS analyst Steven Fisher upgrades United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Neutral to Buy and raises the price target from $335 to $375.

UBS Upgrades United Rentals to Buy, Raises Price Target to $375

JMP Securities analyst Steven Delaney maintains Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) with a Market Outperform and raises the price target from $15 to $17.5.

JMP Securities Maintains Market Outperform on Ready Capital, Raises Price Target to $17.5

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3209378-1&amp;h=3106254754&amp;u=http%3A%2F%2Fregulusrx.com%2F&amp;a=Regulus+Therapeutics+Inc." target="_blank">Regulus Therapeutics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the &quot;Company&quot; or &quot;Regulus&quot;), today announced the presentation of additional data from the first cohort of patients in the Company&#39;s Phase&nbsp;1b&nbsp;clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), as well as new preclinical data from relevant animal models of the disease. The E-poster presentation, titled &quot;Preclinical Evaluation and Results from the First Cohort of Phase&nbsp;1b&nbsp;Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD),&quot; &nbsp;is available to attendees of the PKD Connect Conference 2021, on&nbsp;Friday, June 25, from&nbsp;2-3 p.m. CDT.
The poster presents results from the Company&#39;s ongoing Phase&nbsp;1b&nbsp;study evaluating the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326 in patients with ADPKD. The data demonstrate clinical proof of mechanism by showing target engagement in the kidneys through a statistically significant increase in urinary biomarkers PC1 and PC2, validating miR-17 as a target for ADPKD treatment. Levels of PC1 and PC2 have previously been shown to be inversely correlated with disease severity. RGLS4326 was well-tolerated with no serious adverse events. The poster also describes new data from relevant preclinical models showing treatment with RGLS4326 results in increased gene and polycystin levels&nbsp;in vitro.&nbsp;In addition,&nbsp;improvements in key disease markers including serum creatinine and BUN were demonstrated in the&nbsp;Pkd1(F/RC) mouse model that harbors&nbsp;Pkd1&nbsp;mutation equivalent to human ADPKD.
&quot;These exciting results lend further support to the therapeutic potential of RGLS4326 in ADPKD and also bring us a step closer to our mission to improve the lives of patients suffering from this disease,&quot; commented&nbsp;Jay Hagan, President and Chief Executive Officer of Regulus. &quot;The data from the first cohort of patients in this clinical study suggest that further increases in polycystin levels may be achievable with longer term and, potentially, less frequent, dosing and reinforce our belief that RGLS4326 represents an innovative approach to the treatment of underlying genetic drivers of ADPKD.&quot;
Clinical study details:
RGLS4326 is currently being evaluated in a Phase&nbsp;1b, multicenter, open-label, adaptive design dose-ranging study to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics in patients with ADPKD. In the first cohort of the Phase&nbsp;1b&nbsp;study, nine patients were enrolled and received 4 doses of 1 mg/kg of RGLS4326 administered every other week.
Clinical study results:
<ul>
<li>The data demonstrate clinical proof of mechanism by showing target engagement in the kidneys through statistically significant increases in urinary biomarkers, PC1 and PC2, at study completion compared to baseline.</li>
<li>In addition, one patient with pre-study levels uNGAL almost twice the upper limit of normal saw their uNGAL levels drop into the normal range during the course of the study.</li>
<li>Administration of RGLS4326 was well-tolerated with no serious adverse events.</li>
</ul>
The study is continuing to enroll patients with ADPKD in additional cohorts to evaluate different doses of RGLS4326. The second cohort of patients are receiving a dose of 0.3mg/kg administered every other week and is nearing completion of enrollment.&nbsp;
Preclinical study details:
Pkd1(RC/-) cells were treated with either vehicle, control or RGL4326 for 2 days prior to measuring changes in&nbsp;Pkd1&nbsp;and&nbsp;Pkd2&nbsp;genes, and for 3 days prior to measuring changes in PC1 and PC2 proteins. In addition,&nbsp;Pkd1(F/RC) mice were dosed with either a control or RGLS4326 for four doses prior to assessment of efficacy.
Preclinical study results:
<ul>
<li>RGLS4326 treatment led to increased&nbsp;Pkd1&nbsp;and&nbsp;Pkd2&nbsp;gene expression (&gt;100%&nbsp;increase) and increased levels of their encoded proteins PC1 and PC2 (~50%&nbsp;increase) in&nbsp;Pkd1(RC/-) cells&nbsp;in vitro.</li>
<li>RGLS4326 treatment demonstrated improvement in key efficacy parameters including kidney-weight-to-body-weight ratio (~75%&nbsp;decrease), serum creatinine (~50%&nbsp;decrease) and BUN (~60%&nbsp;decrease) in&nbsp;Pkd1(F/RC) mice compared to control.</li>
</ul>
About RGLS4326 Phase&nbsp;1b
The Phase&nbsp;1b&nbsp;is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD.&nbsp; The study is designed to evaluate the safety, pharmacokinetics, and changes in levels of PC1 and PC2 in patients with ADPKD administered RGLS4326 every other week for a total of four doses.&nbsp; To characterize the effect of RGLS4326 within each cohort, biomarker values at the end of study are compared to baseline values using a two-sided paired t-test. P-values less than 0.05 are considered statistically significant with no adjustment for multiplicity. The dose level for the first cohort is 1mg/kg of RGLS4326 and the dose level for the second cohort is 0.3mg/kg.&nbsp; The third and final cohort will be dosed at a level to be determined based on the results of the first two cohorts.&nbsp;
For more information about the clinical trial design, please visit&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3209378-1&amp;h=1453345896&amp;u=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;a=www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>&nbsp;(NCT04536688).

Biotech

Events

General

RGLS

Regulus Therapeutics To Present Additional Data From Autosomal Dominant Polycystic Kidney Disease Program At PKD Connect 2021 At 2-3 p.m. CDT.

Baird analyst David Manthey upgrades GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Neutral to Outperform and raises the price target from $50 to $58.

Baird Upgrades GMS to Outperform, Raises Price Target to $58

Insider Trades

WLFC

Willis Lease Finance Amended 13D Filing From Chair, CEO Shows Owns 44.44% Stake In Co.

UBS analyst Steven Fisher upgrades Concrete Pumping Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) from Neutral to Buy and raises the price target from $6 to $11.

BBCP

UBS Upgrades Concrete Pumping Holdings to Buy, Raises Price Target to $11

Barclays analyst Benjamin Theurer maintains Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) with a Overweight and raises the price target from $10 to $11.

Barclays Maintains Overweight on Cemex, Raises Price Target to $11

<ul>
<li>PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis</li>
<li>Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis for clinical-readiness in general and initial clinical development of PRS-220 in the post-COVID-19 setting</li>
<li>Clinical development of PRS-220 expected to begin in 2022</li>
</ul>
BOSTON,&nbsp;MA / ACCESSWIRE / June 25,&nbsp;2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin&reg;&nbsp;technology platform for respiratory diseases, cancer, and other indications, today announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF), also known as CCN2, for the treatment of idiopathic pulmonary fibrosis (IPF). The Company also announced it has been selected to receive a 14.2 million euro (approximately 17 million USD) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy for the research and development of PRS-220 for post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also known as post-COVID-19 syndrome pulmonary fibrosis or &quot;long COVID&quot;. Clinical development of the program for both indications is expected to begin next year.
PRS-220 follows Pieris&#39; strategy of deploying its proprietary Anticalin proteins for local interventions on clinically validated targets with the objective of developing superior medicines through more efficient biology. CTGF, a protein localized in the extracellular matrix, is a driver of fibrotic tissue remodeling as a consequence of an aberrant wound healing process. Over-expression of this target in lung tissue is observed in patients suffering from IPF, and clinical data indicate inhibition of CTGF reduces the decline in lung function among these patients. IPF affects over three million patients worldwide and roughly 130,000 patients in the United States. Mean survival is two to five years from the time of diagnosis, with standard of care conferring only modest benefit. The critical function of CTGF in fibrosis, as well as its induced expression upon tissue injury and fibrotic remodeling, render it a compelling intervention for PASC-PF. Persistent symptoms following severe COVID-19 have been reported by different studies in more than one third of hospitalized patients. Pathological changes include impairment of lung function and reduced diffusion capacity of lung for carbon monoxide (DLCO), as well as radiologically detected interstitial lung abnormalities indicative of fibrotic-like impairment of lung tissues. A sub-population of these patients is expected to benefit from an anti-fibrotic treatment, such as PRS-220. There is currently no approved therapy to address PASC-PF.
The grant announced today, intended to support the evaluation of PRS-220 in PASC-PF beyond the intended IPF population, will support clinical-readiness activities and initial clinical development for the program, including GLP tox studies, GMP manufacturing, and phase 1 clinical development. PRS-220 has passed the drug candidate nomination stage within Pieris&#39; pipeline and has several features that reflect its best-in-class potential, including a developability profile demonstrating suitability for inhaled delivery. Pieris intends to present preclinical data for PRS-220 later this year, around which time the Company also plans to provide further program details in IPF and PASC-PF.
&quot;The health consequences of the COVID-19 pandemic will affect our health system for a long time to come. Bavaria&#39;s biotech and pharmaceutical companies are at the forefront of developing new therapies to combat the effects of this virus. Through the strategic grants of the Bavarian Ministry of Economic Affairs, we are providing financial support for particularly innovative therapeutic research projects. We are convinced of the great potential of the PRS-220 program and are therefore promoting its development through a grant of 14.2 million euros,&quot; said Huber Aiwanger, Bavarian State Minister of Economic Affairs, Regional Development and Energy.
&quot;We are excited to unveil our most advanced proprietary inhaled respiratory program and look forward to sharing more details on this program later this year, while actively working to begin clinical development next year. The Bavarian government&#39;s support of innovative drug development is invaluable for both the local biotech ecosystem and broader public health initiatives, and we are grateful for having been selected as a recipient of this grant for PRS-220, which will allow us to accelerate its development and broaden clinical investigation beyond IPF to address an evolving medical need precipitated by the global COVID-19 pandemic that we believe will persist,&quot; said Stephen S. Yoder, President and Chief Executive Officer of Pieris. &quot;Pieris is a pioneer in the inhaled biologics space, and it is gratifying to leverage our respiratory platform to improve the lives of those affected by respiratory diseases such as IPF and COVID-19.&quot;

PIRS

Pieris Pharma Reports Development Of PRS-220 For Idiopathic Pulmonary Fibrosis; $17M Grant From Bavarian Gov't. To Accelerate Program Development For Post-COVID-19 Pulmonary Fibrosis

One of the most common questions traders have about stocks is &ldquo;Why Is It Moving?&rdquo;
That&rsquo;s why Benzinga created the Why Is It Moving, or WIIM, feature in&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a>. WIIMs are a one-sentence description as to why that stock is moving.
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers&nbsp;and following industry trends.
Here are the latest analyst ratings and updates for Nike, Netflix and Nokia.
Telsey Advisory Group analyst Joseph Feldman maintained&nbsp;Nike Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) with an Outperform and raised&nbsp;the price target from&nbsp;$160&nbsp;to&nbsp;$180.
Pivotal Research analyst Mitch Kummetz maintained&nbsp;Nike&nbsp;with a Buy and raised&nbsp;the price target from&nbsp;$167&nbsp;to&nbsp;$175.
Piper Sandler analyst Erinn Murphy maintained&nbsp;Nike with an Overweight and raised&nbsp;the price target from&nbsp;$170&nbsp;to&nbsp;$174.
BMO Capital analyst Simeon Siegel maintained&nbsp;Nike with an Outperform and raised&nbsp;the price target from&nbsp;$160&nbsp;to&nbsp;$174.
Nike shares are trading higher by 11.8% at $149.42&nbsp;after reporting an earnings beat on Thursday afternoon.
Credit Suisse analyst Douglas Mitchelson upgraded&nbsp;Netflix Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>)&nbsp;from Neutral to Outperform and announced&nbsp;a $586&nbsp;price target.
Netflix shares are trading higher by 1.3% at $525.
Goldman Sachs analyst Alexander Duval upgraded&nbsp;Nokia Oyj (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nok#NYSE">NOK</a>)&nbsp;from Neutral to Buy.
Nokia shares are trading higher by 2.7% at $5.28.

Long Ideas

Movers

NFLX

Is Now The Time To Buy Stock Or Options In Nike, Netflix Or Nokia?

Akumin Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKU#NASDAQ">AKU</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AKU#TSX">AKU</a>) (&quot;Akumin&quot;), a premier provider of freestanding outpatient radiology services in the U.S., announced today that it has entered into an agreement to acquire Alliance HealthCare Services, Inc. (&quot;Alliance&quot;), a leading national provider of radiology and oncology solutions to hospitals, health systems and physician groups. The transaction, which has an enterprise value of US$820&nbsp;million, is expected to close in the&nbsp;third quarter&nbsp;of 2021 subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The combined company is expected to have pro forma revenue in excess of US$730&nbsp;million and pro forma adjusted EBITDA in excess of US$210&nbsp;million, including expected cost synergies, based on the last twelve months ended&nbsp;March 31, 2021.
Upon the closing of the transaction (the &quot;Closing&quot;), the combined company will offer the most comprehensive radiology and oncology solutions to patients in the U.S., operating in 46 states, with more than 1,000 hospital and health system customers, 154 independent outpatient radiology centers and 34 radiation therapy centers. The combined company expects to have over 4,000 team members serving more than two million radiology and oncology patient visits annually.
&quot;We have always said Akumin&#39;s vision is to drive patient-centered innovation, service delivery standardization, and exceptional healthcare value, all in an outpatient care setting,&quot; said&nbsp;Riadh Zine, President and CEO of Akumin. &quot;The acquisition of Alliance is transformative in a changing healthcare ecosystem that continues to shift toward outpatient, price-transparent, value-based care. There&#39;s no other organization that has the complement of attributes we will offer together as outpatient healthcare services experts, in particular with Alliance&#39;s longstanding hospital and health system relationships and Akumin&#39;s freestanding operational expertise.&quot;
&quot;Bringing together the best of both organizations for the benefit of our patients, partners and customers is truly exciting,&quot; said&nbsp;Rhonda Longmore-Grund, President and CEO of Alliance. &quot;Alliance brings an over 30-year history of successful radiology and oncology partnerships with hospitals and health systems; and Akumin has built and continues to grow its premier outpatient imaging practice. Together we will offer patients and customers profound value unlike any other healthcare solutions company &ndash; and we can&#39;t wait to get started.&quot;
&quot;We thank the Alliance team for five years of partnership, and we look forward to the success we know Akumin and Alliance will achieve as a combined organization,&quot; said Qisen Huang, Chairman and Founder of Tahoe Investment Group. Tahoe has been majority owner of Alliance since 2016 and will on closing transition to a minority ownership position in the newly combined, publicly traded entity.
An affiliate of Stonepeak, a leading alternative investment firm, has provided a debt and equity financing commitment to Akumin in connection with the acquisition. &quot;We are thrilled to partner with Akumin in this transformative transaction in an effort to help accelerate the company&#39;s growth in the years ahead,&quot; said&nbsp;James Wyper, Senior Managing Director at Stonepeak. &quot;We believe the combined company is well positioned to deliver high-quality, efficient, tech-enabled and patient-centric solutions through its ownership and operation of radiology and oncology infrastructure critical to the healthcare industry.&quot;

TSX:AKU

Akumin Announces Agreement To Acquire Alliance HealthCare Services; Transaction Has Enterprise Value Of $820M

MHLD

Maiden Holdings Reports Will Join Russell 2K Index, Effective Jun. 25

MKM Partners analyst Brett Levy upgrades Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) from Neutral to Buy.

MKM Partners Upgrades Darden Restaurants to Buy

Offerings

SNCR

Synchronoss Prices 38.46M Shares At $2.60/Share

Bristol Myeres Reports Positive CHMP Opinion For Opdivo As Adjuvant Treatment For Esophageal, Gastroesophageal Junction Cancer Patients With Residual Pathologic Disease Following Chemoradiotherapy

<ul>
<li>Telsey Advisory Group boosted NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) price target from $160 to $180. NIKE shares surged 11.2% to $148.53 in pre-market trading.</li>
<li>Citigroup lifted the price target for Ovintiv Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ovv#NYSE">OVV</a>) from $34 to $43. Ovintiv shares rose 0.8% to $32.00 in pre-market trading.</li>
<li>Jefferies boosted Martin Marietta Materials, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mlm#NYSE">MLM</a>) price target from $360 to $424. Martin Marietta Materials shares rose 2.6% to settle at $358.96 on Thursday.</li>
<li>Piper Sandler raised the price target on Signature Bank (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbny#NASDAQ">SBNY</a>) from $270 to $313. Signature Bank shares rose 1.7% to close at $251.35 on Thursday.</li>
<li>RBC Capital raised the price target for GMS Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gms#NYSE">GMS</a>) from $50 to $60. GMS shares rose 2% to $46.00 in pre-market trading.</li>
<li>Jefferies raised Vulcan Materials Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vmc#NYSE">VMC</a>) price target from $180 to $207. Vulcan Materials shares gained 2.3% to $180.00 in pre-market trading.</li>
<li>HC Wainwright &amp; Co. lifted the price target on Aethlon Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aemd#NASDAQ">AEMD</a>) from $5 to $9. Aethlon Medical shares fell 2.4% to $5.20 in pre-market trading.</li>
<li>Credit Suisse boosted FedEx Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdx#NYSE">FDX</a>) price target from $364 to $373. FedEx shares fell 4% to $291.55 in pre-market trading.</li>
<li>Citigroup boosted Accenture plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acn#NYSE">ACN</a>) price target from $310 to $340. Accenture shares rose 0.5% to $292.95 in pre-market trading.</li>
<li>Pivotal Research lifted the price target on NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) from $167to $175. NIKE shares surged 11.2% to $148.53 in pre-market trading.</li>
</ul>
<a href="https://www.benzinga.com/analyst-ratings/price-target/">Check out other big price target changes here</a>

Small Cap

Pre-Market Outlook

AEMD

SBNY

10 Biggest Price Target Changes For Friday

<h3>Gainers</h3>

<ul>
	<li>BIOHARVEST SCIENCES INC (OTC:<a class="ticker" href="/stock/CNVCF#OTC">CNVCF</a>) shares closed up 29.55% at $0.10</li>
	<li>Intec Pharma (NASDAQ:<a class="ticker" href="/stock/NTEC#NASDAQ">NTEC</a>) shares closed up 13.83% at $0.30</li>
	<li>Bloom Energy (NYSE:<a class="ticker" href="/stock/BE#NYSE">BE</a>) shares closed up 8.18% at $13.09</li>
	<li>High Tide (OTC:<a class="ticker" href="/stock/HITIF#OTC">HITIF</a>) shares closed up 6.91% at $0.12</li>
	<li>Cipher Pharms Inc (OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed up 6.83% at $0.96</li>
	<li>GW Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/GWPH#NASDAQ">GWPH</a>) shares closed up 5.56% at $139.54</li>
	<li>GrowGeneration (NASDAQ:<a class="ticker" href="/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 5.42% at $7.20</li>
	<li>Arena Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/ARNA#NASDAQ">ARNA</a>) shares closed up 5.25% at $67.16</li>
</ul>

<h3>Losers</h3>

<ul>
	<li>Elixinol Global (OTC:<a class="ticker" href="/stock/ELLXF#OTC">ELLXF</a>) shares closed down&nbsp;14.55% at $0.11</li>
	<li>48North Cannabis (OTC:<a class="ticker" href="/stock/NCNNF#OTC">NCNNF</a>) shares closed down 14.08% at $0.13</li>
	<li>Heritage Cannabis Holding (OTC:<a class="ticker" href="/stock/HERTF#OTC">HERTF</a>) shares closed down 9.08% at $0.09</li>
	<li>Halo Labs (OTC:<a class="ticker" href="/stock/AGEEF#OTC">AGEEF</a>) shares closed down 8.45% at $0.08</li>
	<li>Tetra Bio Pharma (OTC:<a class="ticker" href="/stock/TBPMF#OTC">TBPMF</a>) shares closed down 6.19% at $0.15</li>
	<li>MariMed (OTC:<a class="ticker" href="/stock/MRMD#OTC">MRMD</a>) shares closed down 5.97% at $0.14</li>
	<li>Auxly Cannabis Group (OTC:<a class="ticker" href="/stock/CBWTF#OTC">CBWTF</a>) shares closed down 5.83% at $0.21</li>
	<li>Vireo Health Intl (OTC:<a class="ticker" href="/stock/VREOF#OTC">VREOF</a>) shares closed down 5.51% at $0.60</li>
	<li>EnWave (OTC:<a class="ticker" href="/stock/NWVCF#OTC">NWVCF</a>) shares closed down 4.93% at $0.76</li>
	<li>4Front Ventures (OTC:<a class="ticker" href="/stock/FFNTF#OTC">FFNTF</a>) shares closed down 4.57% at $0.48</li>
</ul>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis

Penny Stocks

After-Hours Center

Markets

Cannabis Stock Gainers And Losers From July 14, 2020

<h3>Gainers:</h3>

MGC Pharmaceuticals&nbsp;(OTC:<a class="ticker" href="/stock/MGCLF#OTC">MGCLF</a>) shares closed up 165% at&nbsp;$0.026

AusCann Group Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACNNF#OTC">ACNNF</a>) shares closed up 15.68% at $0.11

Intec Pharma&nbsp;(NASDAQ:<a class="ticker" href="/stock/NTEC#NASDAQ">NTEC</a>) shares closed up 11.56% at $0.39

Cipher Pharms Inc&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed up 8.62% at $1.05

Elixinol Global&nbsp;(OTC:<a class="ticker" href="/stock/ELLXF#OTC">ELLXF</a>) shares closed up 8.48% at $0.13

Australis Capital&nbsp;(OTC:<a class="ticker" href="/stock/AUSAF#OTC">AUSAF</a>) shares closed up 7.44% at $0.15

ReneSola&nbsp;(NYSE:<a class="ticker" href="/stock/SOL#NYSE">SOL</a>) shares closed up 6.45% at $1.32

Lexaria Bioscience&nbsp;(OTC:<a class="ticker" href="/stock/LXRP#OTC">LXRP</a>) shares closed up 5.89% at $0.33

Teradyne&nbsp;(NASDAQ:<a class="ticker" href="/stock/TER#NASDAQ">TER</a>) shares closed up 3.84% at $89.74

Green Thumb Industries&nbsp;(OTC:<a class="ticker" href="/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.41% at $11.53

<h3>Losers:</h3>

NexTech AR Solns&nbsp;(OTC:<a class="ticker" href="/stock/NEXCF#OTC">NEXCF</a>) shares closed down 25.79% at $4.95

Nine Energy Service&nbsp;(NYSE:<a class="ticker" href="/stock/NINE#NYSE">NINE</a>) shares closed down 9.59% at $1.79

Axim Biotechnologies&nbsp;(OTC:<a class="ticker" href="/stock/AXIM#OTC">AXIM</a>) shares closed down 9.52% at $0.95

Heritage Cannabis Holding&nbsp;(OTC:<a class="ticker" href="/stock/HERTF#OTC">HERTF</a>) shares closed down 8.4% at $0.09

Acreage Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACRGF#OTC">ACRGF</a>) shares closed down 5.98% at $2.55

Khiron Life Sciences&nbsp;(OTC:<a class="ticker" href="/stock/KHRNF#OTC">KHRNF</a>) shares closed down 5.26% at $0.36

Leviathan Cannabis Group&nbsp;(OTC:<a class="ticker" href="/stock/LVCNF#OTC">LVCNF</a>) shares closed down 5.03% at $0.21

Tetra Bio Pharma&nbsp;(OTC:<a class="ticker" href="/stock/TBPMF#OTC">TBPMF</a>) shares closed down 4.82% at $0.16

cbdMd, Inc.&nbsp;(AMEX:<a class="ticker" href="/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.3% at $2.64

MedMen Enterprises&nbsp;(OTC:<a class="ticker" href="/stock/MMNFF#OTC">MMNFF</a>) shares closed down 3.66% at $0.18

Item 9 Labs&nbsp;(OTC:<a class="ticker" href="/stock/INLB#OTC">INLB</a>) shares closed down 3.17% at&nbsp;$0.90

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From July 20, 2020

<h3>Gainers</h3>

<ul>
	<li>Origin Agritech&nbsp;(NASDAQ:<a class="ticker" href="/stock/SEED#NASDAQ">SEED</a>) shares closed up 28.98% at $13.04</li>
	<li>BIOHARVEST SCIENCES INC&nbsp;(OTC:<a class="ticker" href="/stock/CNVCF#OTC">CNVCF</a>) shares closed up 18.44% at $0.11</li>
	<li>Zenabis Global&nbsp;(OTC:<a class="ticker" href="/stock/ZBISF#OTC">ZBISF</a>) shares closed up 18.18% at $0.08</li>
	<li>Aphria&nbsp;(NASDAQ:<a class="ticker" href="/stock/APHA#NASDAQ">APHA</a>) shares closed up 12.33% at $5.74</li>
	<li>Intec Pharma&nbsp;(NASDAQ:<a class="ticker" href="/stock/NTEC#NASDAQ">NTEC</a>) shares closed up 8.95% at $0.48</li>
	<li>4Front Ventures&nbsp;(OTC:<a class="ticker" href="/stock/FFNTF#OTC">FFNTF</a>) shares closed up 8.9% at $0.53</li>
	<li>Icanic Brands&nbsp;(OTC:<a class="ticker" href="/stock/ICNAF#OTC">ICNAF</a>) shares closed up 8.3% at $0.18</li>
	<li>cbdMd, Inc.&nbsp;(AMEX:<a class="ticker" href="/stock/YCBD#AMEX">YCBD</a>) shares closed up 7.97% at $2.98</li>
	<li>Curaleaf Holdings&nbsp;(OTC:<a class="ticker" href="/stock/CURLF#OTC">CURLF</a>) shares closed up 7.6% at $8.02</li>
	<li>Meridian Bioscience&nbsp;(NASDAQ:<a class="ticker" href="/stock/VIVO#NASDAQ">VIVO</a>) shares closed up 6.74% at $24.71</li>
	<li>AusCann Group Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACNNF#OTC">ACNNF</a>) shares closed up 6.43% at $0.10</li>
	<li>EnWave&nbsp;(OTC:<a class="ticker" href="/stock/NWVCF#OTC">NWVCF</a>) shares closed up 6.38% at $0.73</li>
	<li>Cipher Pharms Inc&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed up 5.38% at $1.15</li>
	<li>Acreage Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACRGF#OTC">ACRGF</a>) shares closed up 5.79% at $2.74</li>
	<li>Teradyne&nbsp;(NASDAQ:<a class="ticker" href="/stock/TER#NASDAQ">TER</a>) shares closed up 5.73% at $88.32</li>
	<li>Green Thumb Industries&nbsp;(OTC:<a class="ticker" href="/stock/GTBIF#OTC">GTBIF</a>) shares closed up 5.18% at $12.82</li>
	<li>Greenlane Holdings&nbsp;(NASDAQ:<a class="ticker" href="/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 4.85% at $3.24</li>
	<li>Cresco Labs&nbsp;(OTC:<a class="ticker" href="/stock/CRLBF#OTC">CRLBF</a>) shares closed up 4.67% at $5.37</li>
	<li>Zynerba Pharmaceuticals&nbsp;(NASDAQ:<a class="ticker" href="/stock/ZYNE#NASDAQ">ZYNE</a>) shares closed up 4.48% at $3.73</li>
	<li>Cronos Group&nbsp;(NASDAQ:<a class="ticker" href="/stock/CRON#NASDAQ">CRON</a>) shares closed up 4.28% at $6.58</li>
	<li>TerrAscend&nbsp;(OTC:<a class="ticker" href="/stock/TRSSF#OTC">TRSSF</a>) shares closed up 4.37% at $2.92</li>
	<li>Corbus Pharmaceuticals&nbsp;(NASDAQ:<a class="ticker" href="/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 3.91% at $7.18</li>
</ul>

<h3>Losers</h3>

<ul>
	<li>Cann Group&nbsp;(OTC:<a class="ticker" href="/stock/CNGGF#OTC">CNGGF</a>) shares closed down&nbsp;17.5% at $0.33</li>
	<li>48North Cannabis&nbsp;(OTC:<a class="ticker" href="/stock/NCNNF#OTC">NCNNF</a>) shares closed down 13.27% at $0.13</li>
	<li>NexTech AR Solns&nbsp;(OTC:<a class="ticker" href="/stock/NEXCF#OTC">NEXCF</a>) shares closed down 11.56% at $5.00</li>
	<li>Axim Biotechnologies&nbsp;(OTC:<a class="ticker" href="/stock/AXIM#OTC">AXIM</a>) shares closed down 10.89% at $0.75</li>
	<li>CordovaCann&nbsp;(OTC:<a class="ticker" href="/stock/LVRLF#OTC">LVRLF</a>) shares closed down 7.74% at $0.30</li>
	<li>Australis Capital&nbsp;(OTC:<a class="ticker" href="/stock/AUSAF#OTC">AUSAF</a>) shares closed down 10.25% at $0.13</li>
	<li>Nine Energy Service&nbsp;(NYSE:<a class="ticker" href="/stock/NINE#NYSE">NINE</a>) shares closed down 6.12% at $1.84</li>
	<li>Cansortium&nbsp;(OTC:<a class="ticker" href="/stock/CNTMF#OTC">CNTMF</a>) shares closed down 5.71% at $0.33</li>
	<li>Nextleaf Solutions&nbsp;(OTC:<a class="ticker" href="/stock/OILFF#OTC">OILFF</a>) shares closed down 5.33% at $0.21</li>
	<li>Psychemedics&nbsp;(NASDAQ:<a class="ticker" href="/stock/PMD#NASDAQ">PMD</a>) shares closed down 4.72% at $4.64</li>
	<li>Bloom Energy&nbsp;(NYSE:<a class="ticker" href="/stock/BE#NYSE">BE</a>) shares closed down 4.08% at $16.22</li>
	<li>CURE Pharmaceutical Hldg&nbsp;(OTC:<a class="ticker" href="/stock/CURR#OTC">CURR</a>) shares closed down 4.62% at $1.65</li>
	<li>InMed Pharmaceuticals&nbsp;(OTC:<a class="ticker" href="/stock/IMLFF#OTC">IMLFF</a>) shares closed down 3.34% at $4.15</li>
</ul>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From July 27, 2020

<h3>Gainers</h3>

<ul>
	<li>Canopy Growth&nbsp;(NYSE:<a class="ticker" href="/stock/CGC#NYSE">CGC</a>) shares closed up 14.86% at $19.48</li>
	<li>MGC Pharmaceuticals&nbsp;(OTC:<a class="ticker" href="/stock/MGCLF#OTC">MGCLF</a>) shares closed up 14.29% at $0.04</li>
	<li>INNER SPIRIT HOLDINGS ORD&nbsp;(OTC:<a class="ticker" href="/stock/INSHF#OTC">INSHF</a>) shares closed up 12.14% at $0.11</li>
	<li>Green Organic Dutchman&nbsp;(OTC:<a class="ticker" href="/stock/TGODF#OTC">TGODF</a>) shares closed up 11.09% at $0.33</li>
	<li>Tilray&nbsp;(NASDAQ:<a class="ticker" href="/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 10.18% at $8.12</li>
	<li>Acreage Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACRGF#OTC">ACRGF</a>) shares closed up 9.67% at $3.00</li>
	<li>Elixinol Global&nbsp;(OTC:<a class="ticker" href="/stock/ELLXF#OTC">ELLXF</a>) shares closed up 9.62% at $0.14</li>
	<li>Lexaria Bioscience&nbsp;(OTC:<a class="ticker" href="/stock/LXRP#OTC">LXRP</a>) shares closed up 9.53% at $0.42</li>
	<li>Aleafia Health&nbsp;(OTC:<a class="ticker" href="/stock/ALEAF#OTC">ALEAF</a>) shares closed up 9.21% at $0.52</li>
	<li>Aurora Cannabis&nbsp;(NYSE:<a class="ticker" href="/stock/ACB#NYSE">ACB</a>) shares closed up 9.13% at $11.65</li>
	<li>Cansortium&nbsp;(OTC:<a class="ticker" href="/stock/CNTMF#OTC">CNTMF</a>) shares closed up 9.09% at $0.36</li>
	<li>Vireo Health Intl&nbsp;(OTC:<a class="ticker" href="/stock/VREOF#OTC">VREOF</a>) shares closed up 8.96% at $0.60</li>
	<li>Greenlane Holdings&nbsp;(NASDAQ:<a class="ticker" href="/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 8.95% at $3.53</li>
	<li>Delta 9 Cannabis&nbsp;(OTC:<a class="ticker" href="/stock/VRNDF#OTC">VRNDF</a>) shares closed up 8.91% at $0.46</li>
	<li>48North Cannabis&nbsp;(OTC:<a class="ticker" href="/stock/NCNNF#OTC">NCNNF</a>) shares closed up 7.61% at $0.14</li>
	<li>Cronos Group&nbsp;(NASDAQ:<a class="ticker" href="/stock/CRON#NASDAQ">CRON</a>) shares closed up 7.6% at $7.08</li>
	<li>Curaleaf Holdings&nbsp;(OTC:<a class="ticker" href="/stock/CURLF#OTC">CURLF</a>) shares closed up 7.2% at $8.60</li>
	<li>TerrAscend&nbsp;(OTC:<a class="ticker" href="/stock/TRSSF#OTC">TRSSF</a>) shares closed up 6.84% at $3.12</li>
	<li>Village Farms Intl&nbsp;(NASDAQ:<a class="ticker" href="/stock/VFF#NASDAQ">VFF</a>) shares closed up 6.21% at $6.33</li>
	<li>MedMen Enterprises&nbsp;(OTC:<a class="ticker" href="/stock/MMNFF#OTC">MMNFF</a>) shares closed up 5.79% at $0.17</li>
	<li>Aphria&nbsp;(NASDAQ:<a class="ticker" href="/stock/APHA#NASDAQ">APHA</a>) shares closed up 4.53% at $6.00</li>
	<li>Liberty Health Sciences&nbsp;(OTC:<a class="ticker" href="/stock/LHSIF#OTC">LHSIF</a>) shares closed up 4.39% at $0.37</li>
	<li>Cresco Labs&nbsp;(OTC:<a class="ticker" href="/stock/CRLBF#OTC">CRLBF</a>) shares closed up 4.35% at $5.61</li>
</ul>

<h3>Losers</h3>

<ul>
	<li>Mexco Energy Corporation Common Stock&nbsp;(AMEX:<a class="ticker" href="/stock/MXC#AMEX">MXC</a>) shares closed down 14.91% at $5.08</li>
	<li>Nova Mentis Life Science&nbsp;(OTC:<a class="ticker" href="/stock/LIBFF#OTC">LIBFF</a>) shares closed up 13.36% at $0.11</li>
	<li>Item 9 Labs&nbsp;(OTC:<a class="ticker" href="/stock/INLB#OTC">INLB</a>) shares closed down 11.24% at $0.77</li>
	<li>Driven Deliveries&nbsp;(OTC:<a class="ticker" href="/stock/DRVD#OTC">DRVD</a>) shares closed down 9.18% at $0.52</li>
	<li>Intec Pharma&nbsp;(NASDAQ:<a class="ticker" href="/stock/NTEC#NASDAQ">NTEC</a>) shares closed down 8.91% at $0.44</li>
	<li>Bloom Energy&nbsp;(NYSE:<a class="ticker" href="/stock/BE#NYSE">BE</a>) shares closed down 7.58% at $14.99</li>
	<li>Cipher Pharms Inc&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed down 6.79% at $1.07</li>
	<li>AusCann Group Holdings&nbsp;(OTC:<a class="ticker" href="/stock/ACNNF#OTC">ACNNF</a>) shares closed down 6.25% at $0.09</li>
	<li>BioHarvest Sciences&nbsp;(OTC:<a class="ticker" href="/stock/CNVCF#OTC">CNVCF</a>) shares closed down 6.19% at $0.10</li>
</ul>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From July 28, 2020

<h3>Gainers:</h3>

<ul>
	<li>AusCann Group Holdings&nbsp;(OTCQX:<a class="ticker" href="/stock/ACNNF#OTCQX">ACNNF</a>) shares closed up 19.9% at $0.12</li>
	<li>4Front Ventures&nbsp;(OTCQX:<a class="ticker" href="/stock/FFNTF#OTCQX">FFNTF</a>) shares closed up 13.95% at $0.66</li>
	<li>TerrAscend&nbsp;(OTCQX:<a class="ticker" href="/stock/TRSSF#OTCQX">TRSSF</a>) shares closed up 8.67% at $3.93</li>
	<li>Harvest Health&nbsp;(OTCQX:<a class="ticker" href="/stock/HRVSF#OTCQX">HRVSF</a>) shares closed up 8.66% at $1.38</li>
	<li>Vireo Health Intl&nbsp;(OTCQX:<a class="ticker" href="/stock/VREOF#OTCQX">VREOF</a>) shares closed up 8.6% at $0.63</li>
	<li>Marrone Bio Innovations&nbsp;(NASDAQ:<a class="ticker" href="/stock/MBII#NASDAQ">MBII</a>) shares closed up 8.27% at $1.44</li>
	<li>CV Sciences&nbsp;(OTCQB:<a class="ticker" href="/stock/CVSI#OTCQB">CVSI</a>) shares closed up 8.23% at $0.71</li>
	<li>Emerald Health&nbsp;(OTCQX:<a class="ticker" href="/stock/EMHTF#OTCQX">EMHTF</a>) shares closed up 7.16% at $0.14</li>
	<li>Charlottes Web Holdings&nbsp;(OTC:<a class="ticker" href="/stock/CWBHD#OTC">CWBHD</a>) shares closed up 6.88% at $3.73</li>
	<li>GrowGeneration&nbsp;(NASDAQ:<a class="ticker" href="/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 5.92% at $13.24</li>
	<li>VIVO Cannabis&nbsp;(OTCQX:<a class="ticker" href="/stock/VVCIF#OTCQX">VVCIF</a>) shares closed up 5.92% at $0.20</li>
	<li>OrganiGram Holdings&nbsp;(NASDAQ:<a class="ticker" href="/stock/OGI#NASDAQ">OGI</a>) shares closed up 5.76% at $1.47</li>
	<li>Aurora Cannabis&nbsp;(NYSE:<a class="ticker" href="/stock/ACB#NYSE">ACB</a>) shares closed up 4.98% at $10.70</li>
	<li>Green Thumb Industries&nbsp;(OTCQX:<a class="ticker" href="/stock/GTBIF#OTCQX">GTBIF</a>) shares closed up 3.62% at $16.01</li>
	<li>Axim Biotechnologies&nbsp;(OTCQB:<a class="ticker" href="/stock/AXIM#OTCQB">AXIM</a>) shares closed up 3.55% at $0.73</li>
	<li>Liberty Health Sciences&nbsp;(OTCQX:<a class="ticker" href="/stock/LHSIF#OTCQX">LHSIF</a>) shares closed up 3.21% at $0.40</li>
</ul>

<h3>Losers:</h3>

<ul>
	<li>48North Cannabis&nbsp;(OTC:<a class="ticker" href="/stock/NCNNF#OTC">NCNNF</a>) shares closed down&nbsp;16.08% at $0.12</li>
	<li>Zenabis Global&nbsp;(OTC:<a class="ticker" href="/stock/ZBISF#OTC">ZBISF</a>) shares closed down 13.54% at $0.09</li>
	<li>Cipher Pharms Inc&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed down 10.74% at $0.97</li>
	<li>BioHarvest Sciences&nbsp;(OTC:<a class="ticker" href="/stock/CNVCF#OTC">CNVCF</a>) shares closed down 8.67% at $0.12</li>
	<li>The Flowr&nbsp;(OTC:<a class="ticker" href="/stock/FLWPF#OTC">FLWPF</a>) shares closed down 8.32% at $0.32</li>
	<li>Intec Pharma&nbsp;(NASDAQ:<a class="ticker" href="/stock/NTEC#NASDAQ">NTEC</a>) shares closed down 7.24% at $0.37</li>
	<li>Canopy Rivers&nbsp;(OTC:<a class="ticker" href="/stock/CNPOF#OTC">CNPOF</a>) shares closed down 5.8% at $0.59</li>
	<li>Greenlane Holdings&nbsp;(NASDAQ:<a class="ticker" href="/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 5.79% at $2.93</li>
	<li>cbdMd, Inc.&nbsp;(AMEX:<a class="ticker" href="/stock/YCBD#AMEX">YCBD</a>) shares closed down 5.65% at $3.17</li>
	<li>CURE Pharmaceutical Hldg&nbsp;(OTCQB:<a class="ticker" href="/stock/CURR#OTCQB">CURR</a>) shares closed down 5.49% at $1.55</li>
	<li>Corbus Pharmaceuticals&nbsp;(NASDAQ:<a class="ticker" href="/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 4.98% at $6.97</li>
	<li>HEXO&nbsp;(NYSE:<a class="ticker" href="/stock/HEXO#NYSE">HEXO</a>) shares closed down 4.79% at $0.77</li>
	<li>Village Farms Intl&nbsp;(NASDAQ:<a class="ticker" href="/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.67% at $5.72</li>
</ul>

&nbsp;

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From August 14, 2020

<h3>GAINERS:</h3>

<ul>
	<li>Nextleaf Solutions&nbsp;(OTC:<a class="ticker" href="/stock/OILFF#OTC">OILFF</a>)&nbsp;shares closed up 15.22% at $0.18</li>
	<li>MedMen Enterprises&nbsp;(OTC:<a class="ticker" href="/stock/MMNFF#OTC">MMNFF</a>) shares closed up 11.96% at $0.18</li>
	<li>Grindrod Shipping Hldgs&nbsp;(NASDAQ:<a class="ticker" href="/stock/GRIN#NASDAQ">GRIN</a>) shares closed up 7.76% at $3.89</li>
	<li>GrowGeneration&nbsp;(NASDAQ:<a class="ticker" href="/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 7.19% at $15.06</li>
	<li>TerrAscend&nbsp;(OTC:<a class="ticker" href="/stock/TRSSF#OTC">TRSSF</a>) shares closed up 6.89% at $4.50</li>
	<li>MariMed&nbsp;(OTC:<a class="ticker" href="/stock/MRMD#OTC">MRMD</a>) shares closed up 5.63% at $0.17</li>
	<li>Encompass Health&nbsp;(NYSE:<a class="ticker" href="/stock/EHC#NYSE">EHC</a>) shares closed up 5.46% at $65.18</li>
	<li>Neptune Wellness Solns&nbsp;(NASDAQ:<a class="ticker" href="/stock/NEPT#NASDAQ">NEPT</a>) shares closed up 5.12% at $2.67</li>
	<li>Item 9 Labs&nbsp;(OTC:<a class="ticker" href="/stock/INLB#OTC">INLB</a>) shares closed up 4.76% at $1.10</li>
	<li>GreenTree Hospitality Gr&nbsp;(NYSE:<a class="ticker" href="/stock/GHG#NYSE">GHG</a>) shares closed up 4.32% at $13.53</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li>Halo Labs&nbsp;(OTC:<a class="ticker" href="/stock/AGEEF#OTC">AGEEF</a>) shares closed down&nbsp;10.59% at $0.8</li>
	<li>Cipher Pharms Inc&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed down 8.91% at $0.87</li>
	<li>ReneSola&nbsp;(NYSE:<a class="ticker" href="/stock/SOL#NYSE">SOL</a>) shares closed down 7.44% at $2.24</li>
	<li>Cansortium&nbsp;(OTC:<a class="ticker" href="/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.19% at $0.34</li>
	<li>Meridian Bioscience&nbsp;(NASDAQ:<a class="ticker" href="/stock/VIVO#NASDAQ">VIVO</a>) shares closed down 6.98% at $14.66</li>
	<li>Teradyne&nbsp;(NASDAQ:<a class="ticker" href="/stock/TER#NASDAQ">TER</a>) shares closed down 5.66% at $84.78</li>
	<li>Genetic Technologies&nbsp;(NASDAQ:<a class="ticker" href="/stock/GENE#NASDAQ">GENE</a>) shares closed down 5.62% at $4.03</li>
	<li>Nine Energy Service&nbsp;(NYSE:<a class="ticker" href="/stock/NINE#NYSE">NINE</a>) shares closed down 5.1% at $1.4</li>
	<li>Green Organic Dutchman&nbsp;(OTC:<a class="ticker" href="/stock/TGODF#OTC">TGODF</a>) shares closed down 4.83% at $0.25</li>
	<li>NexTech AR Solns&nbsp;(OTC:<a class="ticker" href="/stock/NEXCF#OTC">NEXCF</a>) shares closed down 4.57% at $4.63</li>
</ul>

&nbsp;

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Binary Options

Cannabis Stock Gainers And Losers From August 27, 2020

<h4>GAINERS:</h4>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/RLLRF" target="_blank">SugarBud Craft Growers</a>&nbsp;(OTC:<a class="ticker" href="/stock/RLLRF#OTC">RLLRF</a>) shares closed up 26.19% at $0.05</li>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="/stock/CPHRF#OTC">CPHRF</a>) shares closed up 17.11% at $0.89</li>
	<li><a href="https://quotes.benzinga.com/quote/CADMF" target="_blank">Chemesis International</a>&nbsp;(OTC:<a class="ticker" href="/stock/CADMF#OTC">CADMF</a>) shares closed up 16.82% at $0.71</li>
	<li><a href="https://quotes.benzinga.com/quote/SARSF" target="_blank">CANADA HOUSE WELLNESS GRP</a>&nbsp;(OTC:<a class="ticker" href="/stock/SARSF#OTC">SARSF</a>) shares closed up 15.62% at $0.04</li>
	<li><a href="https://quotes.benzinga.com/quote/GGTTF" target="_blank">GTEC Holdings</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/GGTTF#OTCQB">GGTTF</a>) shares closed up 14.2% at $0.72</li>
	<li><a href="https://quotes.benzinga.com/quote/ZYNE" target="_blank">Zynerba Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="/stock/ZYNE#NASDAQ">ZYNE</a>) shares closed up 9.94% at $5.31</li>
	<li><a href="https://quotes.benzinga.com/quote/CRBP" target="_blank">Corbus Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 8.8% at $2.35</li>
	<li><a href="https://quotes.benzinga.com/quote/TBPMF" target="_blank">Tetra Bio Pharma</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/TBPMF#OTCQB">TBPMF</a>) shares closed up 8.02% at $0.16</li>
	<li><a href="https://quotes.benzinga.com/quote/GRWG" target="_blank">GrowGeneration</a>&nbsp;(NASDAQ:<a class="ticker" href="/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 7.94% at $54.78</li>
	<li><a href="https://quotes.benzinga.com/quote/HITIF" target="_blank">High Tide</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/HITIF#OTCQB">HITIF</a>) shares closed up 6.27% at $0.65</li>
	<li><a href="https://quotes.benzinga.com/quote/FFNTF" target="_blank">4Front Ventures</a>&nbsp;(OTCQX:<a class="ticker" href="/stock/FFNTF#OTCQX">FFNTF</a>) shares closed up 6.14% at $1.39</li>
	<li><a href="https://quotes.benzinga.com/quote/BE" target="_blank">Bloom Energy</a>&nbsp;(NYSE:<a class="ticker" href="/stock/BE#NYSE">BE</a>) shares closed up 5.61% at $27.07</li>
	<li><a href="https://quotes.benzinga.com/quote/NEXCF" target="_blank">NexTech AR Solns</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/NEXCF#OTCQB">NEXCF</a>) shares closed up 5.61% at $3.95</li>
	<li><a href="https://quotes.benzinga.com/quote/XXII" target="_blank">22nd Century Group, Inc. Common Stock</a>&nbsp;(AMEX:<a class="ticker" href="/stock/XXII#AMEX">XXII</a>) shares closed up 4.81% at $3.16</li>
	<li><a href="https://quotes.benzinga.com/quote/ARNA" target="_blank">Arena Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="/stock/ARNA#NASDAQ">ARNA</a>) shares closed up 4.17% at $75.92</li>
	<li><a href="https://quotes.benzinga.com/quote/SOL" target="_blank">ReneSola</a>&nbsp;(NYSE:<a class="ticker" href="/stock/SOL#NYSE">SOL</a>) shares closed up 4.13% at $13.10</li>
	<li><a href="https://quotes.benzinga.com/quote/OGI" target="_blank">OrganiGram Holdings</a>&nbsp;(NASDAQ:<a class="ticker" href="/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.91% at $3.99</li>
</ul>

<h4>LOSERS:</h4>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC:<a class="ticker" href="/stock/IVITF#OTC">IVITF</a>) shares closed down 10% at $0.04</li>
	<li><a href="https://quotes.benzinga.com/quote/CVSI" target="_blank">CV Sciences</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/CVSI#OTCQB">CVSI</a>) shares closed down 8.95% at $0.55</li>
	<li><a href="https://quotes.benzinga.com/quote/ELLXF" target="_blank">Elixinol Global</a>&nbsp;(OTC:<a class="ticker" href="/stock/ELLXF#OTC">ELLXF</a>) shares closed down 8.36% at $0.16</li>
	<li><a href="https://quotes.benzinga.com/quote/MGCLF" target="_blank">MGC Pharmaceuticals</a>&nbsp;(OTC:<a class="ticker" href="/stock/MGCLF#OTC">MGCLF</a>) shares closed down 8.33% at $0.06</li>
	<li><a href="https://quotes.benzinga.com/quote/ACNNF" target="_blank">AusCann Group Holdings</a>&nbsp;(OTC:<a class="ticker" href="/stock/ACNNF#OTC">ACNNF</a>) shares closed down 7.27% at $0.10</li>
	<li><a href="https://quotes.benzinga.com/quote/BUGVF" target="_blank">Primo Nutraceuticals</a>&nbsp;(OTC:<a class="ticker" href="/stock/BUGVF#OTC">BUGVF</a>) shares closed down 5% at $0.19</li>
	<li><a href="https://quotes.benzinga.com/quote/CHOOF" target="_blank">Choom Holdings</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/CHOOF#OTCQB">CHOOF</a>) shares closed down 4.94% at $0.13</li>
	<li><a href="https://quotes.benzinga.com/quote/CURR" target="_blank">CURE Pharmaceutical Hldg</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/CURR#OTCQB">CURR</a>) shares closed down 4.76% at $1.00</li>
	<li><a href="https://quotes.benzinga.com/quote/RHNMF" target="_blank">Rhinomed</a>&nbsp;(OTCQB:<a class="ticker" href="/stock/RHNMF#OTCQB">RHNMF</a>) shares closed down 4.27% at $0.11</li>
	<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE:<a class="ticker" href="/stock/NINE#NYSE">NINE</a>) shares closed down 4.19% at $3.20</li>
	<li><a href="https://quotes.benzinga.com/quote/CWBHF" target="_blank">Charlottes Web Holdings</a>&nbsp;(OTCQX:<a class="ticker" href="/stock/CWBHF#OTCQX">CWBHF</a>) shares closed down 3.71% at $4.93</li>
	<li><a href="https://quotes.benzinga.com/quote/MMNFF" target="_blank">MedMen Enterprises</a>&nbsp;(OTCQX:<a class="ticker" href="/stock/MMNFF#OTCQX">MMNFF</a>) shares closed down 3.48% at $0.38</li>
	<li><a href="https://quotes.benzinga.com/quote/YCBD" target="_blank">cbdMd, Inc.</a>&nbsp;(AMEX:<a class="ticker" href="/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.27% at $4.11</li>
	<li><a href="https://quotes.benzinga.com/quote/TRSSF" target="_blank">TerrAscend</a>&nbsp;(OTCQX:<a class="ticker" href="/stock/TRSSF#OTCQX">TRSSF</a>) shares closed down 2.41% at $11.28</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real time following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From March 19, 2021

<h3>GAINERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/GLDFF" target="_blank">Golden Leaf Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLDFF#OTC">GLDFF</a>) shares closed up 9.38% at $0.05</li>
	<li><a href="https://quotes.benzinga.com/quote/NWVCF" target="_blank">EnWave</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.91% at $1.22</li>
	<li><a href="https://quotes.benzinga.com/quote/GABLF" target="_blank">Gaby</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GABLF#OTC">GABLF</a>) shares closed up 6.35% at $0.09</li>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 5.45% at $1.13</li>
	<li><a href="https://quotes.benzinga.com/quote/NDVAF" target="_blank">Indiva</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NDVAF#OTC">NDVAF</a>) shares closed up 4.79% at $0.37</li>
	<li><a href="https://quotes.benzinga.com/quote/VIVO" target="_blank">Meridian Bioscience</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIVO#NASDAQ">VIVO</a>) shares closed up 3.22% at $18.59</li>
	<li><a href="https://quotes.benzinga.com/quote/WRLD" target="_blank">World Acceptance</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) shares closed up 2.97% at $142.77</li>
	<li><a href="https://quotes.benzinga.com/quote/MRMD" target="_blank">MariMed</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 2.56% at $0.77</li>
	<li><a href="https://quotes.benzinga.com/quote/CXXIF" target="_blank">C21 Investments</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 2.54% at $1.12</li>
	<li><a href="https://quotes.benzinga.com/quote/ESE" target="_blank">ESCO Technologies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed up 2.49% at $101.86</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/YCBD" target="_blank">cbdMd, Inc.</a>&nbsp;(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 22.6% at $2.71</li>
	<li><a href="https://quotes.benzinga.com/quote/RHNMF" target="_blank">Rhinomed</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHNMF#OTC">RHNMF</a>) shares closed down 13.56% at $0.10</li>
	<li><a href="https://quotes.benzinga.com/quote/TGODF" target="_blank">Green Organic Dutchman</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGODF#OTC">TGODF</a>) shares closed down 11.74% at $0.25</li>
	<li><a href="https://quotes.benzinga.com/quote/HERTF" target="_blank">Heritage Cannabis Holding</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HERTF#OTC">HERTF</a>) shares closed down 9.76% at $0.09</li>
	<li><a href="https://quotes.benzinga.com/quote/EPWCF" target="_blank">Empower Clinics</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/EPWCF#OTC">EPWCF</a>) shares closed down 8.58% at $0.45</li>
	<li><a href="https://quotes.benzinga.com/quote/GGTTF" target="_blank">GTEC Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GGTTF#OTC">GGTTF</a>) shares closed down 8.21% at $0.48</li>
	<li><a href="https://quotes.benzinga.com/quote/UGRO" target="_blank">Urban-gro</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 7.93% at $7.08</li>
	<li><a href="https://quotes.benzinga.com/quote/GRIN" target="_blank">Grindrod Shipping Hldgs</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#NASDAQ">GRIN</a>) shares closed down 7.67% at $7.82</li>
	<li><a href="https://quotes.benzinga.com/quote/NEPT" target="_blank">Neptune Wellness Solns</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPT#NASDAQ">NEPT</a>) shares closed down 6.9% at $1.08</li>
	<li><a href="https://quotes.benzinga.com/quote/MMNFF" target="_blank">MedMen Enterprises</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MMNFF#OTC">MMNFF</a>) shares closed down 6.82% at $0.31</li>
	<li><a href="https://quotes.benzinga.com/quote/TBPMF" target="_blank">Tetra Bio-Pharma</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TBPMF#OTC">TBPMF</a>) shares closed down 6.8% at $0.27</li>
	<li><a href="https://quotes.benzinga.com/quote/CRBP" target="_blank">Corbus Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 6.71% at $1.39</li>
	<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVITF#OTC">IVITF</a>) shares closed down 6.67% at $0.04</li>
	<li><a href="https://quotes.benzinga.com/quote/INLB" target="_blank">Item 9 Labs</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/INLB#OTC">INLB</a>) shares closed down 6.38% at $3.08</li>
	<li><a href="https://quotes.benzinga.com/quote/CNPOF" target="_blank">RIV Capital</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 5.85% at $1.39</li>
	<li><a href="https://quotes.benzinga.com/quote/TLRY" target="_blank">Tilray</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.85% at $13.68</li>
	<li><a href="https://quotes.benzinga.com/quote/VREOF" target="_blank">Vireo Health Intl</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VREOF#OTC">VREOF</a>) shares closed down 5.7% at $1.97</li>
	<li><a href="https://quotes.benzinga.com/quote/CURLF" target="_blank">Curaleaf Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 5.51% at $13.74</li>
	<li><a href="https://quotes.benzinga.com/quote/ACB" target="_blank">Aurora Cannabis</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NYSE">ACB</a>) shares closed down 4.81% at $7.33</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time&nbsp;following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From May 13, 2021

<h3>GAINERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 15,8% at $1,33</li>
	<li><a href="https://quotes.benzinga.com/quote/GRIN" target="_blank">Grindrod Shipping Hldgs</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#NASDAQ">GRIN</a>) shares closed up 10,91% at $9,86</li>
	<li><a href="https://quotes.benzinga.com/quote/CVSI" target="_blank">CV Sciences</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 10,24% at $0,46</li>
	<li><a href="https://quotes.benzinga.com/quote/BMMJ" target="_blank">Body and Mind</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 9,79% at $0,36</li>
	<li><a href="https://quotes.benzinga.com/quote/HSTRF" target="_blank">Hollister Biosciences</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HSTRF#OTC">HSTRF</a>) shares closed up 6,75% at $0,30</li>
	<li><a href="https://quotes.benzinga.com/quote/MBII" target="_blank">Marrone Bio Innovations</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBII#NASDAQ">MBII</a>) shares closed up 6,51% at $1,80</li>
	<li><a href="https://quotes.benzinga.com/quote/ACNNF" target="_blank">AusCann Group Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACNNF#OTC">ACNNF</a>) shares closed up 4,47% at $0,10</li>
	<li><a href="https://quotes.benzinga.com/quote/CURR" target="_blank">CURE Pharmaceutical Hldg</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURR#OTC">CURR</a>) shares closed up 4,02% at $0,73</li>
	<li><a href="https://quotes.benzinga.com/quote/ARNA" target="_blank">Arena Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARNA#NASDAQ">ARNA</a>) shares closed up 3,82% at $64,66</li>
	<li><a href="https://quotes.benzinga.com/quote/GHG" target="_blank">GreenTree Hospitality Gr</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) shares closed up 3,72% at $15,07</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/MGCLF" target="_blank">MGC Pharmaceuticals</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGCLF#OTC">MGCLF</a>) shares closed down 9,9% at $0,04</li>
	<li><a href="https://quotes.benzinga.com/quote/SNDL" target="_blank">Sundial Growers</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 9,65% at $1,03</li>
	<li><a href="https://quotes.benzinga.com/quote/ZLDAF" target="_blank">Zelira Therapeutics</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDAF#OTC">ZLDAF</a>) shares closed down 8,91% at $0,04</li>
	<li><a href="https://quotes.benzinga.com/quote/TGODF" target="_blank">Green Organic Dutchman</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGODF#OTC">TGODF</a>) shares closed down 7,81% at $0,32</li>
	<li><a href="https://quotes.benzinga.com/quote/INLB" target="_blank">Item 9 Labs</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/INLB#OTC">INLB</a>) shares closed down 7,18% at $3,23</li>
	<li><a href="https://quotes.benzinga.com/quote/TLRY" target="_blank">Tilray</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 6,44% at $20,05</li>
	<li><a href="https://quotes.benzinga.com/quote/CWBHF" target="_blank">Charlottes Web Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 5,75% at $4,36</li>
	<li><a href="https://quotes.benzinga.com/quote/CBWTF" target="_blank">Auxly Cannabis Group</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 4,76% at $0,23</li>
	<li><a href="https://quotes.benzinga.com/quote/HEXO" target="_blank">HEXO</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#NYSE">HEXO</a>) shares closed down 4,62% at $6,61</li>
	<li><a href="https://quotes.benzinga.com/quote/GRWG" target="_blank">GrowGeneration</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 4,58% at $41,64</li>
	<li><a href="https://quotes.benzinga.com/quote/XXII" target="_blank">22nd Century Group</a>&nbsp;(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XXII#AMEX">XXII</a>) shares closed down 4,63% at $4,54</li>
	<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) shares closed down 3,78% at $2,29</li>
	<li><a href="https://quotes.benzinga.com/quote/OGI" target="_blank">OrganiGram Holdings</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 3,36% at $3,16</li>
	<li><a href="https://quotes.benzinga.com/quote/ACB" target="_blank">Aurora Cannabis</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 3,32% at $9,89</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real time following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From June 10, 2021

<h3>GAINERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVITF#OTC">IVITF</a>) shares closed up 13.46% at $0.06</li>
	<li><a href="https://quotes.benzinga.com/quote/NTEC" target="_blank">Intec Pharma</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTEC#NASDAQ">NTEC</a>) shares closed up 13.35% at $4.50</li>
	<li><a href="https://quotes.benzinga.com/quote/CNVCF" target="_blank">BioHarvest Sciences</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNVCF#OTC">CNVCF</a>) shares closed up 5.95% at $0.24</li>
	<li><a href="https://quotes.benzinga.com/quote/PMD" target="_blank">Psychemedics</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMD#NASDAQ">PMD</a>) shares closed up 5.17% at $8.34</li>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 4.35% at $1.44</li>
	<li><a href="https://quotes.benzinga.com/quote/MMNFF" target="_blank">MedMen Enterprises</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MMNFF#OTC">MMNFF</a>) shares closed up 3.02% at $0.27</li>
	<li><a href="https://quotes.benzinga.com/quote/ARNA" target="_blank">Arena Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARNA#NASDAQ">ARNA</a>) shares closed up 2.27% at $66.40</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/ZLDAF" target="_blank">Zelira Therapeutics</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDAF#OTC">ZLDAF</a>) shares closed up 10% at $0.03</li>
	<li><a href="https://quotes.benzinga.com/quote/EPWCF" target="_blank">Empower Clinics</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/EPWCF#OTC">EPWCF</a>) shares closed up 8.76% at $0.54</li>
	<li><a href="https://quotes.benzinga.com/quote/CURR" target="_blank">CURE Pharmaceutical Hldg</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURR#OTC">CURR</a>) shares closed up 7.75% at $0.66</li>
	<li><a href="https://quotes.benzinga.com/quote/BMMJ" target="_blank">Body and Mind</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 7.37% at $0.35</li>
	<li><a href="https://quotes.benzinga.com/quote/LVCNF" target="_blank">Leviathan Natural Prods</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVCNF#OTC">LVCNF</a>) shares closed up 7.02% at $0.44</li>
	<li><a href="https://quotes.benzinga.com/quote/FLOOF" target="_blank">Flower One Hldgs</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/FLOOF#OTC">FLOOF</a>) shares closed up 6.5% at $0.19</li>
	<li><a href="https://quotes.benzinga.com/quote/SEED" target="_blank">Origin Agritech</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) shares closed up 6.11% at $9.38</li>
	<li><a href="https://quotes.benzinga.com/quote/CNGGF" target="_blank">Cann Gr</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed up 6.09% at $0.30</li>
	<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) shares closed up 5.78% at $2.77</li>
	<li><a href="https://quotes.benzinga.com/quote/AUSAF" target="_blank">Australis Capital</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed up 4.88% at $0.20</li>
	<li><a href="https://quotes.benzinga.com/quote/FLWPF" target="_blank">The Flowr</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/FLWPF#OTC">FLWPF</a>) shares closed up 4.45% at $0.2</li>
	<li><a href="https://quotes.benzinga.com/quote/TLRY" target="_blank">Tilray</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 3.64% at $17.47</li>
	<li><a href="https://quotes.benzinga.com/quote/NWVCF" target="_blank">EnWave</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.27% at $0.86</li>
	<li><a href="https://quotes.benzinga.com/quote/SNDL" target="_blank">Sundial Growers</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 2.98% at $0.96</li>
	<li><a href="https://quotes.benzinga.com/quote/CBWTF" target="_blank">Auxly Cannabis Group</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 2.94% at $0.23</li>
	<li><a href="https://quotes.benzinga.com/quote/CRBP" target="_blank">Corbus Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 2.82% at $2.07</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From June 17, 2021

<h3>GAINERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/MXC" target="_blank">Mexco Energy</a>&nbsp;(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>)&nbsp;shares closed up 23.34% at $9.78</li>
	<li><a href="https://quotes.benzinga.com/quote/ELLXF" target="_blank">Elixinol Wellness</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>)&nbsp;shares closed up 9.24% at $0.11</li>
	<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>)&nbsp;shares closed up 8.99% at $3.03</li>
	<li><a href="https://quotes.benzinga.com/quote/BMMJ" target="_blank">Body and Mind</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>)&nbsp;shares closed up 8.64% at $0.35</li>
	<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVITF#OTC">IVITF</a>)&nbsp;shares closed up 8.26% at $0.06&nbsp;</li>
	<li><a href="https://quotes.benzinga.com/quote/TBPMF" target="_blank">Tetra Bio-Pharma</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TBPMF#OTC">TBPMF</a>)&nbsp;shares closed up 7.66% at $0.30</li>
	<li><a href="https://quotes.benzinga.com/quote/CVSI" target="_blank">CV Sciences</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>)&nbsp;shares closed up 7.66% at $0.41</li>
	<li><a href="https://quotes.benzinga.com/quote/SOLCF" target="_blank">SOL Global Investments</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>)&nbsp;shares closed up 6.88% at $2.95</li>
	<li><a href="https://quotes.benzinga.com/quote/EAST" target="_blank">Eastside Distilling</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>)&nbsp;shares closed up 6.41% at $2.99</li>
	<li><a href="https://quotes.benzinga.com/quote/CNPOF" target="_blank">RIV Capital</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>)&nbsp;shares closed up 6.28% at $1.46</li>
	<li><a href="https://quotes.benzinga.com/quote/GNLN" target="_blank">Greenlane Hldgs</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>)&nbsp;shares closed up 6.12% at $3.99</li>
	<li><a href="https://quotes.benzinga.com/quote/KSHB" target="_blank">KushCo Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/KSHB#OTC">KSHB</a>)&nbsp;shares closed up 5.55% at $0.97</li>
	<li><a href="https://quotes.benzinga.com/quote/VFF" target="_blank">Village Farms Intl</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>)&nbsp;shares closed up 5.11% at $10.50</li>
	<li><a href="https://quotes.benzinga.com/quote/MMNFF" target="_blank">MedMen Enterprises</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MMNFF#OTC">MMNFF</a>)&nbsp;shares closed up 3.27% at $0.26</li>
	<li><a href="https://quotes.benzinga.com/quote/WRLD" target="_blank">World Acceptance</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>)&nbsp;shares closed up 3.22% at $167.89</li>
	<li><a href="https://quotes.benzinga.com/quote/ACB" target="_blank">Aurora Cannabis</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>)&nbsp;shares closed up 2.75% at $8.97</li>
	<li><a href="https://quotes.benzinga.com/quote/TLRY" target="_blank">Tilray</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>)&nbsp;shares closed up 2.72% at $17.37</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/MGCLF" target="_blank">MGC Pharmaceuticals</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGCLF#OTC">MGCLF</a>)&nbsp;shares closed down 10.34% at $0.03</li>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>)&nbsp;shares closed down 5.75% at $1.26</li>
	<li><a href="https://quotes.benzinga.com/quote/SOL" target="_blank">ReneSola</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>)&nbsp;shares closed down 5.56% at $7.82</li>
	<li><a href="https://quotes.benzinga.com/quote/ACNNF" target="_blank">AusCann Group Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACNNF#OTC">ACNNF</a>)&nbsp;shares closed down 5.33% at $0.08</li>
	<li><a href="https://quotes.benzinga.com/quote/SEED" target="_blank">Origin Agritech</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>)&nbsp;shares closed down 5.25% at $8.66</li>
	<li><a href="https://quotes.benzinga.com/quote/ITHUF" target="_blank">iAnthus Capital Hldgs</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>)&nbsp;shares closed down 4.37% at $0.19</li>
	<li><a href="https://quotes.benzinga.com/quote/VVCIF" target="_blank">VIVO Cannabis</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VVCIF#OTC">VVCIF</a>)&nbsp;shares closed down 4.36% at $0.11</li>
	<li><a href="https://quotes.benzinga.com/quote/MRMD" target="_blank">MariMed</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>)&nbsp;shares closed down 3.77% at $1.02</li>
	<li><a href="https://quotes.benzinga.com/quote/TRSSF" target="_blank">TerrAscend</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>)&nbsp;shares closed down 3.5% at $10.03</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From June 21, 2021

<h3>GAINERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/HRVOF" target="_blank">Harvest One Cannabis</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HRVOF#OTC">HRVOF</a>) shares closed up 10.96% at $0.08</li>
	<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 6.35% at $1.34</li>
	<li><a href="https://quotes.benzinga.com/quote/HERTF" target="_blank">Heritage Cannabis Holding</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HERTF#OTC">HERTF</a>) shares closed up 5.29% at $0.08</li>
	<li><a href="https://quotes.benzinga.com/quote/SEED" target="_blank">Origin Agritech</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) shares closed up 5.08% at $9.10</li>
	<li><a href="https://quotes.benzinga.com/quote/NEPT" target="_blank">Neptune Wellness Solns</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPT#NASDAQ">NEPT</a>) shares closed up 4.17% at $1.25</li>
	<li><a href="https://quotes.benzinga.com/quote/SOL" target="_blank">ReneSola</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.7% at $8.12</li>
	<li><a href="https://quotes.benzinga.com/quote/GRWG" target="_blank">GrowGeneration</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 2.53% at $42.16</li>
	<li><a href="https://quotes.benzinga.com/quote/BLOZF" target="_blank">Cannabix Technologies</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 2.34% at $0.87</li>
	<li><a href="https://quotes.benzinga.com/quote/MBII" target="_blank">Marrone Bio Innovations</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBII#NASDAQ">MBII</a>) shares closed up 2.29% at $1.79</li>
</ul>

<h3>LOSERS:</h3>

<ul>
	<li><a href="https://quotes.benzinga.com/quote/MXC" target="_blank">Mexco Energy</a>&nbsp;(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 8.80% at $8.81</li>
	<li><a href="https://quotes.benzinga.com/quote/ELLXF" target="_blank">Elixinol Wellness</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 8.46% at $0.11</li>
	<li><a href="https://quotes.benzinga.com/quote/PMD" target="_blank">Psychemedics</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMD#NASDAQ">PMD</a>) shares closed down 7.72% at $7.29</li>
	<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVITF#OTC">IVITF</a>) shares closed down 5.93% at $0.05</li>
	<li><a href="https://quotes.benzinga.com/quote/CNGGF" target="_blank">Cann Gr</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 5.19% at $0.29</li>
	<li><a href="https://quotes.benzinga.com/quote/TRSSF" target="_blank">TerrAscend</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>) shares closed down 4.9% at $9.53</li>
	<li><a href="https://quotes.benzinga.com/quote/INLB" target="_blank">Item 9 Labs</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/INLB#OTC">INLB</a>) shares closed down 4.76% at $3.00</li>
	<li><a href="https://quotes.benzinga.com/quote/KSHB" target="_blank">KushCo Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/KSHB#OTC">KSHB</a>) shares closed down 4.64% at $0.93</li>
	<li><a href="https://quotes.benzinga.com/quote/NXGWF" target="_blank">Next Green Wave Holdings</a>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NXGWF#OTC">NXGWF</a>) shares closed down 4.43% at $0.64</li>
	<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) shares closed down 4.23% at $2.92</li>
</ul>

<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time following this link.</a>

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis Stock Gainers And Losers From June 22, 2021

ACNNF

ACRGF

AGEEF

ALEAF

APHA

ARNA

AUSAF

AXIM

BLOZF

BMMJ

BUGVF

CADMF

CBWTF

CHOOF

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRBP

CRLBF

CRON

CURLF

CURR

CVSI

CWBHD

CWBHF

CXXIF

DRVD

EAST

ELLXF

EMHTF

EPWCF

FFNTF

FLOOF

FLWPF

GABLF

GENE

GGTTF

GLDFF

GNLN

GRIN

GRWG

GTBIF

GWPH

HERTF

HEXO

HITIF

HRVOF

HRVSF

HSTRF

ICNAF

IMLFF

INLB

INSHF

ITHUF

IVITF

KHRNF

KSHB

LHSIF

LIBFF

LVCNF

LVRLF

LXRP

MBII

MGCLF

MMNFF

MRMD

NCNNF

NDVAF

NEPT

NEXCF

NINE

NTEC

NWVCF

NXGWF

OILFF

RHNMF

RLLRF

SARSF

SEED

SNDL

SOLCF

TBPMF

TGODF

TLRY

TRSSF

UGRO

VIVO

VREOF

VRNDF

VVCIF

WRLD

XXII

YCBD

ZBISF

ZLDAF

ZYNE

Cipher Pharmaceuticals (CPHRF) CEO, Craig Mull on Q2 2020 Results - Earnings Call Transcript

Cipher Pharmaceuticals' (CPHRF) CEO Craig Mull on Q3 2020 Results - Earnings Call Transcript

Cipher Pharmaceuticals, Inc. (CPHRF) CEO Craig Mull on Q4 2020 Results - Earnings Call Transcript

Cipher Pharmaceuticals enters automatic repurchase plan

Cipher Pharmaceuticals, Inc. (CPHRF) CEO Craig Mull on Q1 2021 Results - Earnings Call Transcript

Recent Quotes

Related Companies

Cipher Pharmaceuticals Frequently Asked Questions

How do I buy Cipher Pharmaceuticals (CPHRF) stock?

Who are Cipher Pharmaceuticals's (CPHRF) competitors?

What is the target price for Cipher Pharmaceuticals (CPHRF) stock?

Current Stock Price for Cipher Pharmaceuticals (CPHRF)?

Does Cipher Pharmaceuticals (CPHRF) pay a dividend?

When is Cipher Pharmaceuticals (OTC:CPHRF) reporting earnings?

Is Cipher Pharmaceuticals (CPHRF) going to split?

What sector and industry does Cipher Pharmaceuticals (CPHRF) operate in?